Description of efficacy and indications of Serputinib/Serpatinib (Ruitu) Capsules

Selpercatinib is a highly selective RET tyrosine kinase inhibitor that mainly inhibits the growth and division of tumor cells by targeting and blocking signaling caused by RET gene fusion or mutation. The drug was originally developed to target RET-driven cancers for which traditional chemotherapy or non-targeted drugs have limited efficacy, and represents another milestone in molecular targeted therapy.

Seputinib was first approved by the US FDA in 2020 for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutated medullary thyroid carcinoma (MTC), and thyroid cancer patients confirmed to be RET fusion-positive. Its mechanism of action is based on accurately identifying abnormal RET signals and blocking cancer cell signaling networks by inhibiting kinase activation, causing tumor cells to lose their ability to continue growing. Compared with earlier non-specific multi-target drugs, seputinib is significantly optimized in terms of selectivity and tolerability.

The drug dosage form is oral capsule, common specifications include40mg and 80mg. Patients usually take it twice daily, and there is no significant interaction with food, making it convenient for long-term medication. After the capsule is absorbed in the body, it is quickly distributed in the blood and tumor tissue, and has good penetration into the central nervous system, which is particularly important for advanced patients with brain metastasis.

In clinical use, seputinib is often used in patients with advanced or metastatic RET-positive cancer that cannot be controlled by surgery or radiotherapy. The doctor will determine whether it is suitable based on the individual genetic test results and combine it with other treatment options for comprehensive management. Studies have shown that many patients have significantly reduced tumor size and improved quality of life after taking the drug. Because the drug is highly selective and has little impact on non-target cells, most of the common side effects, such as mild fatigue, dry mouth or increased blood pressure, are controllable.

Reference:https://en.wikipedia.org/wiki/Selpercatinib